Chapter 6: AAD Use in Different Patient Populations, and a Patient-Centric Approach to Optimal Patient Management - 28/09/23
, Allen J. Solomon, MD c, Kamala P. Tamirisa, MD dRésumé |
Associated with longer life expectancy, greater survival of patients with cardiovascular disorders, and increased use of wearable and insertable/implantable devices capable of detection, the frequency of atrial fibrillation (AF) diagnosis is increasing. This chapter describes two representative patient cases that were used to enable a discussion of the evaluation and management of AF in different scenarios. One patient is young and healthy with paroxysmal AF but no major comorbidities (though there is a family history of AF). The other is older with multiple complicating comorbidities. These cases sparked an active discussion among the panelists that demonstrated not only the multitude of considerations when choosing the optimal therapy for each individual, but also the individualistic differences in biases and styles that can exist between experts in the field. The results of these discussions revealed agreement that:
(1) | Considerations in rhythm control therapy should be based on individual patient needs. |
(2) | Most antiarrhythmic drugs (AADs) have multichannel effects; these may be important determinants of their antiarrhythmic actions and non-cardiac effects. |
(3) | Increasing awareness among healthcare providers (HCPs) of the properties of AADs helps them anticipate potential pro- or antiarrhythmic effects. |
(4) | It is important for HCPs to involve patients (and caregivers) in decisions about their health using shared decision-making approaches. |
Keywords : Atrial fibrillation, rhythm control, antiarrhythmic, shared decision making
Plan
Vol 205 - N° S1
P. S19-S21 - octobre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
